Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

Elena J. Orlando, Xia Han, Catherine Tribouley, Patricia A. Wood, Rebecca J. Leary, Markus Riester, John E. Levine, Muna Qayed, Stephan A. Grupp, Michael Boyer, Barbara De Moerloose, Eneida Nemecek, Henrique Bittencourt, Hidefumi Hiramatsu, Jochen Buechner, Stella M. Davies, Michael R. Verneris, Kevin Nguyen, Jennifer L. Brogdon, Hans Bitter & 5 others Michael Morrissey, Piotr Pierog, Serafino Pantano, Jeffrey A. Engelman, Wendy Winckler

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19 relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells and are predicted to lead to a truncated protein with a nonfunctional or absent transmembrane domain and consequently to a loss of surface antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination CAR approach.

Original languageEnglish (US)
Pages (from-to)1504-1506
Number of pages3
JournalNature Medicine
Volume24
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Antigen Receptors
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antigens
Mutation
Loss of Heterozygosity
Surface Antigens
Recurrence
Tumors
Therapeutics
Cells
Neoplasms
Proteins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Orlando, E. J., Han, X., Tribouley, C., Wood, P. A., Leary, R. J., Riester, M., ... Winckler, W. (2018). Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nature Medicine, 24(10), 1504-1506. https://doi.org/10.1038/s41591-018-0146-z

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. / Orlando, Elena J.; Han, Xia; Tribouley, Catherine; Wood, Patricia A.; Leary, Rebecca J.; Riester, Markus; Levine, John E.; Qayed, Muna; Grupp, Stephan A.; Boyer, Michael; De Moerloose, Barbara; Nemecek, Eneida; Bittencourt, Henrique; Hiramatsu, Hidefumi; Buechner, Jochen; Davies, Stella M.; Verneris, Michael R.; Nguyen, Kevin; Brogdon, Jennifer L.; Bitter, Hans; Morrissey, Michael; Pierog, Piotr; Pantano, Serafino; Engelman, Jeffrey A.; Winckler, Wendy.

In: Nature Medicine, Vol. 24, No. 10, 01.10.2018, p. 1504-1506.

Research output: Contribution to journalArticle

Orlando, EJ, Han, X, Tribouley, C, Wood, PA, Leary, RJ, Riester, M, Levine, JE, Qayed, M, Grupp, SA, Boyer, M, De Moerloose, B, Nemecek, E, Bittencourt, H, Hiramatsu, H, Buechner, J, Davies, SM, Verneris, MR, Nguyen, K, Brogdon, JL, Bitter, H, Morrissey, M, Pierog, P, Pantano, S, Engelman, JA & Winckler, W 2018, 'Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia', Nature Medicine, vol. 24, no. 10, pp. 1504-1506. https://doi.org/10.1038/s41591-018-0146-z
Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nature Medicine. 2018 Oct 1;24(10):1504-1506. https://doi.org/10.1038/s41591-018-0146-z
Orlando, Elena J. ; Han, Xia ; Tribouley, Catherine ; Wood, Patricia A. ; Leary, Rebecca J. ; Riester, Markus ; Levine, John E. ; Qayed, Muna ; Grupp, Stephan A. ; Boyer, Michael ; De Moerloose, Barbara ; Nemecek, Eneida ; Bittencourt, Henrique ; Hiramatsu, Hidefumi ; Buechner, Jochen ; Davies, Stella M. ; Verneris, Michael R. ; Nguyen, Kevin ; Brogdon, Jennifer L. ; Bitter, Hans ; Morrissey, Michael ; Pierog, Piotr ; Pantano, Serafino ; Engelman, Jeffrey A. ; Winckler, Wendy. / Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. In: Nature Medicine. 2018 ; Vol. 24, No. 10. pp. 1504-1506.
@article{230df87c80f04bc982ceaf893aac8a6c,
title = "Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia",
abstract = "We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19– relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells and are predicted to lead to a truncated protein with a nonfunctional or absent transmembrane domain and consequently to a loss of surface antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination CAR approach.",
author = "Orlando, {Elena J.} and Xia Han and Catherine Tribouley and Wood, {Patricia A.} and Leary, {Rebecca J.} and Markus Riester and Levine, {John E.} and Muna Qayed and Grupp, {Stephan A.} and Michael Boyer and {De Moerloose}, Barbara and Eneida Nemecek and Henrique Bittencourt and Hidefumi Hiramatsu and Jochen Buechner and Davies, {Stella M.} and Verneris, {Michael R.} and Kevin Nguyen and Brogdon, {Jennifer L.} and Hans Bitter and Michael Morrissey and Piotr Pierog and Serafino Pantano and Engelman, {Jeffrey A.} and Wendy Winckler",
year = "2018",
month = "10",
day = "1",
doi = "10.1038/s41591-018-0146-z",
language = "English (US)",
volume = "24",
pages = "1504--1506",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

AU - Orlando, Elena J.

AU - Han, Xia

AU - Tribouley, Catherine

AU - Wood, Patricia A.

AU - Leary, Rebecca J.

AU - Riester, Markus

AU - Levine, John E.

AU - Qayed, Muna

AU - Grupp, Stephan A.

AU - Boyer, Michael

AU - De Moerloose, Barbara

AU - Nemecek, Eneida

AU - Bittencourt, Henrique

AU - Hiramatsu, Hidefumi

AU - Buechner, Jochen

AU - Davies, Stella M.

AU - Verneris, Michael R.

AU - Nguyen, Kevin

AU - Brogdon, Jennifer L.

AU - Bitter, Hans

AU - Morrissey, Michael

AU - Pierog, Piotr

AU - Pantano, Serafino

AU - Engelman, Jeffrey A.

AU - Winckler, Wendy

PY - 2018/10/1

Y1 - 2018/10/1

N2 - We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19– relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells and are predicted to lead to a truncated protein with a nonfunctional or absent transmembrane domain and consequently to a loss of surface antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination CAR approach.

AB - We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19– relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells and are predicted to lead to a truncated protein with a nonfunctional or absent transmembrane domain and consequently to a loss of surface antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination CAR approach.

UR - http://www.scopus.com/inward/record.url?scp=85054482344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054482344&partnerID=8YFLogxK

U2 - 10.1038/s41591-018-0146-z

DO - 10.1038/s41591-018-0146-z

M3 - Article

VL - 24

SP - 1504

EP - 1506

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 10

ER -